Juno Pharmaceuticals and Celltrion have announced an Australian “co-marketing partnership” that will see the pair collaborate on marketing for Celltrion’s Herzuma (trastuzumab) and Truxima (rituximab) biosimilars.
“Celltrion Healthcare Australia, a division of the biosimilar developer Celltrion Healthcare, are the marketing authorization holders in Australia for these...





